GALT Stock Overview
A clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Galectin Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.72 |
| 52 Week High | US$4.27 |
| 52 Week Low | US$1.28 |
| Beta | 0.72 |
| 1 Month Change | -22.29% |
| 3 Month Change | 40.93% |
| 1 Year Change | 73.25% |
| 3 Year Change | -29.35% |
| 5 Year Change | -31.66% |
| Change since IPO | -77.33% |
Recent News & Updates
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25
Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09Shareholder Returns
| GALT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.8% | -1.2% | -1.2% |
| 1Y | 73.2% | 4.7% | 21.5% |
Return vs Industry: GALT exceeded the US Biotechs industry which returned 4.7% over the past year.
Return vs Market: GALT exceeded the US Market which returned 21.5% over the past year.
Price Volatility
| GALT volatility | |
|---|---|
| GALT Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GALT's share price has been volatile over the past 3 months.
Volatility Over Time: GALT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 28 | Joel Lewis | galectintherapeutics.com |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration.
Galectin Therapeutics Inc. Fundamentals Summary
| GALT fundamental statistics | |
|---|---|
| Market cap | US$168.38m |
| Earnings (TTM) | -US$44.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs GALT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$44.78m |
| Earnings | -US$44.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -119.1% |
How did GALT perform over the long term?
See historical performance and comparison